All In Biotech

Drug Trial Radar · NCT07154511

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Prabesh KanelAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Farmer Family Foundation
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to answer are: 1. Does tributyrin improve memory/thinking test scores and walking/balance ability? 2. What medical problems do participants have when taking tributyrin? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no drug) to see if tributyrin works to treat Parkinson disease symptoms. Participants will: 1. Take tributyrin 3 times a day for 80-100 days 2. Complete motor and cognitive testing at the clinic before and after the supplementation period 3. Complete brain imaging (MRI scans and PET scans) before and after the supplementation period.

Conditions

  • Parkinson Disease
  • Parkinson Disease Dementia

Interventions

  • TributyrinDrug

    Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

  • PlaceboDrug

    Participants will take 500mg TID placebo for 90 days +/- 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single composite global cognitive z-scoreTime frame: Baseline and post-intervention (83-97 days after starting supplement)
  2. Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III ScoreTime frame: Baseline and post-intervention (83-97 days after starting supplement)
  3. Safety and tolerability of tributyrinTime frame: During and after 83-97 day supplementation period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Domino's Farms

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.